Welcome to our dedicated page for Pavmed news (Ticker: PAVMZ), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. reports developments for a diversified commercial-stage medical technology company operating across medical devices, diagnostics and digital health. News about PAVmed commonly covers business updates and financial results, Nasdaq listing compliance, convertible-debt and balance-sheet actions, and activity at subsidiaries such as Lucid Diagnostics and Veris Health.
Recurring updates include Lucid Diagnostics' commercial activity around the EsoGuard esophageal precancer test, insurance coverage and direct-contracting channels, and Veris Health's financing and development work for an implantable physiological monitor. PAVmed also discusses its incubator strategy, subsidiary financing, and capital-structure steps tied to its Nasdaq-listed common stock and Series Z warrants.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a multi-product medical device company, announced that Lishan Aklog, M.D., Chairman and CEO, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 15, 2020, from 8:00 a.m. to 8:30 a.m. Eastern time. Interested parties can listen to the webcast on PAVmed's investor relations website. PAVmed aims to innovate and commercialize products addressing unmet clinical needs in diverse areas, leveraging a proprietary business model to enhance value creation and expand its product pipeline.
PAVmed Inc. (NASDAQ:PAVM, PAVMZ) will present at the LD 500 investor conference on September 3, 2020, at 7:20 a.m. PST / 10:20 a.m. EST. CEO Lishan Aklog, M.D., will provide a corporate overview to attendees.
This conference, running from September 1-4, is notable as it is accessible to everyone, a first for LD Micro, which aims to showcase unique companies in the capital markets despite challenges posed by COVID-19. PAVmed is recognized for its innovative medical device solutions.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) reported significant advancements despite COVID-19 challenges. Key achievements include a preliminary CMS payment determination for EsoGuard™, FDA clearance for the CarpX™ device, and the launch of both products. The company expanded its commercial management team, activated clinical trials for EsoGuard, and secured funding of approximately $10.6 million. Financially, PAVmed experienced a GAAP net loss of $5.6 million for Q2 2020. Upcoming activities focus on commercial expansion and clinical trial progress.